Select Page

3 Q&A Interview with Ivana, Group CEO, OptimaPharm

Jun 28, 2022

Q1: Why has Optimapharm chosen to join Medicon Valley Alliance?

A: Growing in the Nordics is just one of our development plans which is why having the well-established nordic Crown CRO join the Optimapharm family was so important. As Crown and Optimapharm had been strong partners for over 10 years, this was a natural move of Crown CRO joining the Optimapharm group as our Nordic headquarter. We understand the importance that MVA is playing by connecting life science companies to further science, innovations, treatments and cures. We are excited to be part of an alliance that helps Denmark and Sweden achieve this.

Q2: What are the unique features of Optimapharm that would help the life sciences in Denmark and Sweden?

A: We are a pan-european mid-sized CRO with 25 offices operating in 37 countries and 550+ Employees.  Our long experience, fast start-up times and cost-effective full-service solutions will help pharma, biotech and medtech companies succeed in taking their products further. We offer the unique ability to perform projects with in-house personnel in each country for Danish and Swedish life science companies. Optimapharm allows companies to have part of their study performed locally in the Nordics and North America (with our strong partners) but remaining cost-effective by including our unrivalled access to the Baltics, western Europe and eastern European regions.

Q3: How has Optimapharm been affected by the covid pandemic?

A: The pandemic taught us that our 2 strongest assets (our employees and being flexible) continued to support clients during this difficult time. By investing into our employees safety and well-being with remote working options, it allowed us to continue to grow as a company in a healthy and productive way. During these times we have grown organically and through acquisitions. We have remained focused on helping clients in a flexible way so that we can blend on-site with remote to successfully complete projects.

3 Q&A interviews